Three experimental injectable antiretrovirals – a novel capsid inhibitor and two next-generation integrase inhibitors – could ...

For decades, scientists have recognized that human immunodeficiency virus (HIV) is a formidable viral pathogen. After years of probing work and extensive experimentation, a Yale research team has ...

– Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – – Latest Data from the PURPOSE Program Further Demonstrates the ...

A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral ...

A dual-action HIV antibody–drug conjugate forces Env to open, then blocks it, boosting virus neutralization up to tenfold in the lab.

For millions of people living with HIV, a daily regimen of medications is a lifelong necessity. If they stop taking the drugs—commonly referred to as antiretroviral therapy—the virus usually rushes ...

A new single-pill HIV treatment has proved as effective as regimens of up to 11 tablets a day in suppressing the virus in hard-to-treat patients. It’s “a potential breakthrough for a growing cohort of ...

Every person with HIV needs treatment for the rest of their life. For some, this means 10 or more drugs taken throughout each day. But as NPR's Gabrielle Emanuel reports, a study shows there's new ...

Harerimana Ismail of Uganda is a community health worker who checks on kids with HIV. He lost his salary after the Trump ...

What are the three types of HIV tests available to patients, how do they differ, and how can patients determine the best ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented ...